The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim

References

• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85:174-80
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009a;113:2161-71
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395-403
   PubMed Web of Science ®Google Scholar
• George JN, Lyons R, Cuevas FJ, et al. Health-related Quality of Life (HRQoL) in patients with Chronic Immune Thrombocytopenic Purpura (ITP): results from two placebo-controlled phase 3 studies of AMG 531 in Blood 2007;110:1314
   Google Scholar
• McMillan R, Bussel J, George J, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83:150-4
   PubMed Web of Science ®Google Scholar
• Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 2008;24:2767-76
   PubMed Web of Science ®Google Scholar
• Saleh MN, Fisher M, Grotzinger KM. Analysis of the impact and burden of illness of adult chronic ITP in the US. Curr Med Res Opin 2009;25:2961-9
   PubMed Web of Science ®Google Scholar
• Mikhael J, Danese M, Kessler CM, et al. Initial and long-term outcomes of splenectomy in adult Immune Thrombocytopenic Purpura (ITP) patients: a systematic review and meta-analysis. Blood (ASH Annual Meeting Abstracts) 2007;110:Abstract 1321
   Google Scholar
• Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost 2011;37:621-30
   PubMedGoogle Scholar
• Bussel JB. Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematol Oncol Clin North Am 2009;23:1329-41
   PubMedGoogle Scholar
• Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010;2010:377-84
   PubMed Web of Science ®Google Scholar
• McCrae K. Immune thrombocytopenia: no longer ‘idiopathic'. Cleve Clin J Med 2011;78:358-73
   PubMedGoogle Scholar
• Salama A. Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol 2011;4:107-18
   PubMed Web of Science ®Google Scholar
• Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011;9:262-73
   PubMed Web of Science ®Google Scholar
• Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011;152:52-60
   PubMedGoogle Scholar
• Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 2011;365:734-41
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Romiplostim. Cancer Treat Res 2011;157:267-88
   PubMedGoogle Scholar
• Stasi R, Bosworth J, Rhodes E, et al. Thrombopoietic agents. Blood Rev 2010;24:179-90
   PubMed Web of Science ®Google Scholar
• Zeng Y, Duan X, Xu J, et al. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011;(7):CD008235
   Google Scholar
• Cuker A, Chiang EY, Cines DB. Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf 2010;5:171-1
   PubMedGoogle Scholar
• Cersosimo RJ. Romiplostim in chronic immune thrombocytopenic purpura. Clin Ther 2009;31:1887-907
   PubMedGoogle Scholar
• Ghanima W. Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol 2010;47:258-65
   PubMed Web of Science ®Google Scholar
• Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci 2011;1222:55-63
   PubMed Web of Science ®Google Scholar
• Newland A. Thrombopoietin receptor agonists in the treatment of thrombocytopenia. Curr Opin Hematol 2009;16:357-64
   PubMed Web of Science ®Google Scholar
• Perreault S, Burzynski J. Romiplostim: a novel thrombopoiesis-stimulating agent. Am J Health Syst Pharm 2009;66:817-24
   PubMedGoogle Scholar
• Mowatt G, Boachie C, Crowther M, et al. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. Health Technol Assess 2009;13(2 Suppl):63-8
   PubMedGoogle Scholar
• NICE -- National Institute for Health and Clinical Excellence. NICE technology appraisal guidance: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. 2011. http://guidance.nice.org.uk/TA221. Accessed February 27, 2012
   Google Scholar
• Australian Government Department of Health and Aging. Public summary documents by product: Romiplostim. 2010 [accessed 2012 Feb 27]; Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-romiplostim-mar10; http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-Romiplostin-july10. Accessed February 27, 2012
   Google Scholar
• CEDAC Final recommendation: Romiplostim. 2010. http://www.cadth.ca/media/cdr/complete/cdr_complete_Nplate_May-27-2010.pdf. Accessed February 27, 2012
   Google Scholar
• Danese MD, Lindquist K, Gleeson M, et al. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol 2009;84:631-5
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Rodeghiero F. Classification, pathophysiology and epidemiology of thrombocytopenias. Haematologica 2009;94(4 Suppl):q-r
   Google Scholar
• Tarantino MD, Mathias SD, Snyder CF, et al. Impact of ITP on physician visits and workplace productivity. Curr Med Res Opin 2010;26:319-28
   PubMed Web of Science ®Google Scholar
• Khellaf M, Le Moine JG, Poitrinal P, et al. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol 2011;90:441-6
   PubMed Web of Science ®Google Scholar
• Lucioni C, Mazzi S, Chiroli S, et al. Retrospective cohort evaluation of the burden of illness among individuals receiving treatment for Chronic Immune Thrombocytopenic Purpura in Italy: Final Report for Amgen Europe GmbH, PharmacoEconomics -- Italian Research Articles 2009;11(2):93-102
   Google Scholar
• Aledort LM, Lyons RM, Okano G, et al. The clinical and direct medical cost burden of splenectomy among managed care patients with chronic Immune Thrombocytopenic Purpura (ITP). Blood (ASH Annual Meeting Abstracts) 2006;108:Abstract 5536
   Google Scholar
• U.S. Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims: Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, 2009. p 65132-3
   Google Scholar
• Kuhne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011;96:1831-7
   PubMed Web of Science ®Google Scholar
• Kurata Y, Fujimura K, Kuwana M, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol 2011;93:329-35
   PubMed Web of Science ®Google Scholar
• Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-74
   PubMed Web of Science ®Google Scholar
• Norgaard M, Jensen AO, Engebjerg MC, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 2011;117:3514-20
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009;145:235-44
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93
   PubMed Web of Science ®Google Scholar
• European Commission. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medical products. Off J Eur Commun 2000;L18:L18/11-L18/15
   Google Scholar
• Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009;83:83-9
   PubMed Web of Science ®Google Scholar
• Bottiger LE, Westerholm B. Thrombocytopenia. I. Incidence and aetiology. Acta Med Scand 1972;191:535-40
   PubMed Web of Science ®Google Scholar
• Franco-Garcia E, Giraldo P, Bernal M, et al. Which are the true incidence rates of primary hematological disorders acquired in our population? Sangre (Barc) 1998;43:356-64
   PubMedGoogle Scholar
• Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13
   PubMed Web of Science ®Google Scholar
• Feudjo-Tepie MA, Le Roux G, Beach KJ, et al. Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv Hematol 2009;2009:963506
   PubMedGoogle Scholar
• Segal J, Powe N. Prevalence of immune thrombocytopenia: analysis of administrative data. J Thromb Haemost 2006;4:2377-83
   PubMed Web of Science ®Google Scholar
• Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711-2; author reply 713
   PubMed Web of Science ®Google Scholar
• Landgren O, Gridley G, Fears TR, et al. Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans. Blood 2006;108:1111-2
   PubMed Web of Science ®Google Scholar
• Enger C, Bennett D, Forssen U, et al. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol 2010;92:289-95
   PubMed Web of Science ®Google Scholar
• George JN, Woolf SH, Raskob GE, et al. Idiopathic Thrombocytopenic Purpura: a practice guideline developed by explicit methods for The American Society of Hematology. Blood 1996;88:3-40
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-8
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54
   PubMed Web of Science ®Google Scholar
• Provan D, Newland A, Norfolk D, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-96
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86
   PubMed Web of Science ®Google Scholar
• Neunert CW, Crowther M, Cohen A, et al; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:17
   Google Scholar
• Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;330:1560-4
   PubMed Web of Science ®Google Scholar
• Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425-42
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-42
   PubMed Web of Science ®Google Scholar
• Zimmer J, Andres E, Noel E, et al. Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. Clin Lab Haematol 2004;26:137-42
   PubMedGoogle Scholar
• Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991;77:31-3
   PubMed Web of Science ®Google Scholar
• Aledort LM, Lyons RM, Okano G, et al. Retrospective matched cohort study of Immune Thrombocytopenic Purpura (ITP): complications related to Corticosteroid (CS) use. Blood (ASH Annual Meeting Abstracts) 2006a;108:Abstract 3295
   Google Scholar
• Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359:23-9
   PubMed Web of Science ®Google Scholar
• Gutierrez-Espindola GR, Morales-Polanco MR, Guerro-Rivera SG, et al. High doses of dexamethasone in adult patients with Idiopathic Thrombocytopenic Purpura. Arch Med Res 2003;34:31-4
   PubMedGoogle Scholar
• Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64
   PubMed Web of Science ®Google Scholar
• Reid IR. Glucocorticoid osteoporosis–mechanisms and management. Eur J Endocrinol 1997;137:209-17
   PubMed Web of Science ®Google Scholar
• Stasi R, Brunetti M, Pagano A, et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000;26:582-6
   PubMed Web of Science ®Google Scholar
• Talecris Biotherapeutics Inc. Gamunex® (Immune Globulin Intravenous) Prescribing Information. Talecris Biotherapeutics Inc., Los Angeles, CA, US, 2008
   Google Scholar
• Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689-700
   PubMed Web of Science ®Google Scholar
• Baxter Healthcare Corporation. WinRho SDF Efficacy Information [accessed October, 2009]. Baxter Healthcare Corporation, Deerfield Illinois, Dec 2010
   Google Scholar
• American Society of Health-System Pharmacists (ASHP). Rituximab: AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2010
   Google Scholar
• Alasfoor K, Alrasheed M, Alsayegh F, et al. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol 2009;88:239-43
   PubMed Web of Science ®Google Scholar
• Jacoub J, Mchlayeh W, Tabbara I, et al. The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia. Blood 2004;104:1b-416b
   PubMedGoogle Scholar
• Lieb JV, Rossetti JM, Shadduck RK, et al. Rituximab therapy for relapsed or refractory autoimmune thrombocytopenia. Blood 2003;102:1b-512b
   PubMedGoogle Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33
   PubMed Web of Science ®Google Scholar
• Neunert C. Idiopathic thrombocytopenic purpura: advances in management. Clin Adv Hematol Oncol 2011;9:404-6
   PubMedGoogle Scholar
• Gadenstatter M, Lamprecht B, Klingler A, et al. Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. Am J Surg 2002;184:606-9; discussion 609–10
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with spenectomy: a population based cohort study. Ann Intern Med 2009;151:546-555
   PubMed Web of Science ®Google Scholar
• Winslow ER, Brunt LM. Perioperative outcomes of laparoscopic versus open splenectomy: a meta-analysis with an emphasis on complications. Surgery 2003;134:647-55
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34
   PubMed Web of Science ®Google Scholar
• Nichol JL. Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells 1998;16(2 Suppl):165-75
   PubMedGoogle Scholar
• GlaxoSmithKline. PROMACTA® (eltrombopag) Prescribing Information. GlaxoSmithKline, Research Triangle Park, NC, USA, 2008
   Google Scholar
• Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-99
   PubMed Web of Science ®Google Scholar
• Weitz IC, Sanz MA, Henry DH, et al. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012;28 (5):1-8
   Google Scholar
• Stasi R, Murali M, Michel M, et al. Evaluation of bleeding-related episodes in patients with Immune Thrombocytopenia (ITP) receiving romiplostim or medical standard of care. Int J Hematol 2012 May 5. [Epub ahead of print]
   Google Scholar
• Gernsheimer T, Kuter DJ, Cines DB, et al. Analysis of mortality rates during romiplostim clinical studies of patients (Pts) with immune thrombocytopenia (ITP). Blood (ASH Annual Meeting Abstracts) 2010b;116:1518-9 (Abstract 3701)
   Google Scholar
• Kuter D, Bussel J, Newland A. Long-term efficacy and safety of romiplostim treamtent of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. Blood (ASH Annual Meeting Abstracts) 2010;16:36-7 (Abstract 3701)
   Google Scholar
• Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am 2007;21:743-59, vii
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008;143:16-26
   PubMed Web of Science ®Google Scholar
• Adams JR, Nathan DP, Bennett CL. Pharmacoeconomics of therapy for ITP: steroids, IVIg, anti-D, and splenectomy. Blood Rev 2002;16:65-7
   PubMedGoogle Scholar
• Blackhouse G, Xie F, Campbell K, et al. Intravenous immunoglobulin for treatment of idiopathic thrombocytopenic purpura: economic and health service impact analyses. Technology Report Issue 112. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2008
   Google Scholar
• Brosa M, Arocho R, Gutierrez L, et al. A pharmacoeconomic evaluation of romiplostim (NPLATE) for the treatment of chronic immune thrombocytopenia (ITP). Value Health 2010;13:A464 (Abstract PSY425)
   Google Scholar
• Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46:741-53
   PubMed Web of Science ®Google Scholar
• Estrada-Gomez R, Vargas-Castro O, Oropeza-Borges M, et al. A single-institution, 20-year prospective experience with an affordable Fc-receptor blockade method to treat patients with chronic, refractory autoimmune thrombocytopenic purpura. Rev Invest Clin 2007;59:424-7
   PubMedGoogle Scholar
• Xie F, Blackhouse G, Assasi N, et al. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura. Clin Ther 2009;31:1082-91; discussion 1066-88
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ. The Pocketbook: pharmacoeconomic issues related to intravenous immunoglobulin therapy. Pharmacotherapy 2005;25:94S-100S
   PubMed Web of Science ®Google Scholar
• Heng LL, Caguioa P, Chin NS, et al. Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region. Int J Hematol 2011;94:142-9
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Stepanski EJ, Walker MS, et al. Implications of IV monoclonal antibody infustion reaction for the patient, caregiver, and practice: results of a multicenter study. Supportive Care in Cancer 2009;17:91-8
   PubMedGoogle Scholar
• Keidar A, Feldman M, Szold A. Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count. Am J Hematol 2005;80:95-100
   PubMed Web of Science ®Google Scholar
• Mikhael J, Northridge K, Lindquist K, et al. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. American Journal of Hematology 2009;84:743-8
   PubMedGoogle Scholar
• Vainchtock A, Bogillot O, Divine M, et al. Use of an administrative database to estimate the number of hospital admissions for immune thrombocytopenic purpura and its economic burden in France. Value Health 2008;11:A647
   Google Scholar
• Young J, Deuson R, Isitt J. Impact of Immune Thrombocytopenic Purpura on health care resource use and workplace productivity. Value Health 2008;11:A167 (Abstract PSY148)
   Google Scholar
• Nelson M, Gadberry T, Northridge K, et al. Mortality and cost associated with hospitalization for immune thrombocytopenia purpura (ITP). American Society of Health-System Pharmacists Midyear Conference, Las Vegas, NV, Dec 2--6, 2007
   Google Scholar
• Nelson M, Guo M, Gao S, et al. Analysis of health care resource utilization (HCRU) and hospitalization in patients with Chronic Immune Thrombocytopenic Purpura (ITP) in HOPA, 2008
   Google Scholar
• Chiche L, Lefrere F, Chulikavit M, et al. Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia (ITP) in France. Value Health 2011;14:A415
   Google Scholar
• Gadberry T, Nelson M, Gao SK. Health care resource utilization in the management of chronic Immune Thrombocytopenic Purpura (ITP): analyses of administrative data. American Society of Health-System Pharmacists Midyear Conference, Las Vegas, NV, Dec 2--6, 2007
   Google Scholar
• Lu ZJ, Danese M, Halperin M, et al. Clinical and economic outcomes associated with emergency department visits in patients with immune thrombocytopenia. Blood 2011;118:Abstract 4209
   Google Scholar
• Szende A, Brazier J, Schaefer C, et al. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin 2010;26:1893-903
   PubMed Web of Science ®Google Scholar
• Zhou Z, Yang L, Chen Z, et al. Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. Eur J Haematol 2007;78:518-23
   PubMed Web of Science ®Google Scholar
• George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009;144:409-15
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. Haematologica 2003;88:1081-7
   PubMed Web of Science ®Google Scholar
• Mathias SD, Gao SK, Miller KL, et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008;6:13
   PubMed Web of Science ®Google Scholar
• McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-14
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Gandek B. SF-36® Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 2003
   Google Scholar
• Brooks R, Euro QoL Group. EuroQol: the current state of play. Health Policy 1996;37:19
   PubMedGoogle Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007a;5:11
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007b;29:950-62
   PubMed Web of Science ®Google Scholar
• Mathias SD, Gao SK, Rutstein M, et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin 2009;25:375-83
   PubMed Web of Science ®Google Scholar
• Northridge K, Danese M, Deuson R. Pharmacoeconomic evaluation of romiplostim for the treatment of primary adult chronic immune thrombocytopenia (ITP) in AMCP’s 23rd Annual Meeting & Showcase, Minneapolis, MN, April 23-27, 2011
   Google Scholar
• Pettigrew M, Deuson R, Garces K. Comparative net cost impact of the utilization of Nplate (romiplostim) and Intravenous Immunoglobulin (IVIg) for the treatment of patients with Immune Thrombocytopenia (ITP) in Ontario. J Popul Ther Clin Pharmacol 2011;18:e192-e193 (Abstract 131)
   Google Scholar
• Arocho R, Northridge K, Rivera Hurtado R, et al. A pharmacoeconomic evaluation of Romiplostim (Nplate®) for the treatment of Chronic Immune Thrombocytopenia (ITP) in Mexico. Value Health 2010;14:A62 (Abstract PSY17)
   Google Scholar
• Kuter DJ, Mathias S, Rummel M, et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol 2012;87 (5):558-561
   Google Scholar
• Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health 2011;14:90-6
   PubMed Web of Science ®Google Scholar
• Nelson M, Guo DM, Gao SK, et al. Analysis of Health Care Resource Utilization (HCRU) and hospitalization in patients with Chronic Immune Thrombocytopenic Purpura (ITP) in 2008 4th Annual HOPA Conference, 2008
   Google Scholar